Therapeutic effects of crizotinib in lung cancer and the treatment after drug resistance
10.3760/cma.j.issn.1673-422X.2016.07.013
- VernacularTitle:克唑替尼治疗肺癌的疗效及其耐药后的治疗
- Author:
Liyang ZHU
;
Zhonghe YU
- Publication Type:Journal Article
- Keywords:
Lung neplasms;
Drug resistance,neoplasm;
Therapy
- From:
Journal of International Oncology
2016;43(7):532-534
- CountryChina
- Language:Chinese
-
Abstract:
Crizotinib is a tyrosine kinase inhibitor (TKI),which is a target for echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK).It can prolong the progression free survival (PFS)of ALK positive patients with advanced non-small cell lung cancer (NSCLC).The median PFS in the first-line and second-line mPFS is 10.9 months and 7.7 months.However,despite an initial benefit,patients inevitably experience tumor progression,due to the ALK fusion gene amplification and secondary mutations of ALK kinase domain.Clinical trials show the promising efficacy like next generation ALK inhibitors and heat shock protein 90 (HSP90)can overcome acquired resistance.
